ClinicalTrials.gg
CompletedNCT07446491Updated Oct 22, 2026

A Study to Evaluate the Safety and Efficacy of PN20 in the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Undergoing an Elective Procedure

A Phase 1/2 interventional study of PN20 and Placebo in Thrombocytopenia Associated With Chronic Liver Disease, sponsored by Chongqing Peg-Bio Biopharm Co., Ltd.. Completed at 8 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-22.

Sponsored by Chongqing Peg-Bio Biopharm Co., Ltd. · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Registered 8 months after the study started (first participant enrolled Jun 2025, registered Feb 2026).
Updated Oct 22, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
54
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 108 studies in Thrombocytopenia with a site in China — 42 open to participants now, 45 under way, 10 of them phase 3. Thrombocytopenia · China.

Enrollment
60th of 96
54 · median 82
Started
2025
with 17 others
Phase 1/2
4 of 108
1 open now
Registered
99th of 108
by date

Among the 108 studies in Thrombocytopenia with a site in China, this one is the 60th largest by enrollment of the 96 interventional ones that give a count, is one of 18 that started in 2025, is one of 4 in phase 1/2, and was the 99th registered.

Thrombocytopenia

484 studies on the registry are indexed under Thrombocytopenia; 102 are open to participants now.

Browse Thrombocytopenia studies →

Open to participants now

42 of the 108 studies in Thrombocytopenia with a site in China are open now. Recruiting first, the newest first:

37 more — sign in →

All 42 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 66 Thrombocytopenia studies recruiting now, 44 (67%) set no upper age limit and 18 (27%) stop at 75 or younger; 10 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 108 studies in Thrombocytopenia with a site in China, or all of them as a file.
02

Study summary

The main aim of this clinical trial is to assess the safety and efficacy of a single dose of PN20 in treatment of thrombocytopenia in adult patients with chronic liver disease undergoing an elective procedure. The main questions it aims to answer are:

  • How effective is PN20 in treating thrombocytopenia in patients with chronic liver disease?
  • Is PN20 safe in these patients? Participants will
  • Receive a single subcutaneous injections of PN20 or placebo according to weight before an elective procedure,
  • Visit the clinic for assessment.
Read the detailed description

This is aan open-label, single-dose, dose-escalation phase Ib/II study conducted in two stages, Phase Ib and Phase II, designed to evaluate the safety, tolerability, efficacy, PK, PD, and immunogenicity of PN20 in patients with CLDT in patients with CLDT.

Phase Ib stage is an open-label, single-dose, dose-escalation study. Three dose levels (8 participants per group) will be administered sequentially from low to high.

Phase 2 stage is a randomized, double-blind, single-dose, placebo-controlled study. Eligible patients are randomized in a 1:1 ratio to the treatment or placebo group following informed consent. The dosing regimen in the treatment group is selected based on the Phase Ib results, with one or two dose levels selected. If two PN20 dose levels are selected, randomization follows a 1:1:1 ratio to one of the two treatment groups or to the placebo group.

03

Conditions studied

  • Thrombocytopenia Associated With Chronic Liver Disease

Browse trials for

Keywords

  • PN20
  • Thrombocytopenia
  • Chronic Liver Disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years, Male or female
  • Diagnosed with chronic liver disease-related thrombocytopenia (baseline count \< 50 × 10⁹/L), score A or B;
  • Planned elective invasive procedure or minor surgery within Days 7-15 post-enrollment, excluding laparotomy, thoracotomy, craniotomy, open-heart surgery, organ resection, or partial organ resection (for tissue and other types of tissue resection, enrollment is permitted if the investigator considers the risk of bleeding and invasiveness to be comparable to or lower than that of the procedures listed in the surgical examples list);
  • (ECOG) performance status score of 0 or 1;
  • Women of must have a negative pregnancy test
  • Agree to use reliable through 3 months post-study.
  • Participants must understand the study requirements and provide written .

Exclusion criteria

Exclusion Criteria:

  • The following conditions or medical history:

    • Presence of other conditions that may lead to thrombocytopenia;
    • History of thrombotic or significant cardiovascular events;
    • Uncontrolled bleeding;
    • Advanced liver cancer;
    • Severe comorbidities;
  • Currently using or with a history of the following treatments:

    • Recent major surgery or splenectomy;
    • Liver transplant;
    • Recent therapies affecting counts;
  • Significant lab abnormalities;
  • Recent participation in other clinical trials;
  • Known to the productstudy drug;
  • Active substance abuse;
  • Any condition deemed by the investigator to compromise safety or study integrity.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
54 participants (actual)

Study arms

  • Experimental
    PN20 treatment group (1~2 dose goups)

    A single subcutaneous injection

    Drug: PN20

  • Placebo comparator
    Placebo

    A single subcutaneous injection

    Drug: Placebo

Interventions

  • DrugPN20

    subcutaneous injection

  • DrugPlacebo

    subcutaneous injection

06

What researchers measure

Primary outcomes

  1. The proportion of responders

    Based on the results of hematology tests, calculate the proportion of participants whose platelet counts remained ≥50×10⁹/L from 24 hours pre-surgery through 7 days post-surgery without requiring rescue treatment for bleeding.

    Time frame: 8 days (from 24 hours pre-surgery through 7 days post-surgery)

Secondary outcomes

  1. Adverse Events

    Incidence and severity of all adverse events related to PN20 observed through vital signs, physical examinations, 12-lead ECGs, clinical laboratory tests (including hematology, urinalysis, blood chemistry, coagulation function, and pregnancy tests for women of childbearing potential)

    Time frame: From dosing of PN20 (Day 1) to Day 28

  2. Cmax

    Maximum Plasma Concentration

    Time frame: From pre-dose to 8 days after dosing

  3. AUC

    Area Under the Plasma Concentration-time Curve

    Time frame: From pre-dose to 8 days after dosing

  4. Immunogenicity of PN20

    Using a validated ELISA assay to detect ADAs against the thrombopoietic peptide and polyethylene glycol

    Time frame: From pre-dose to 28 days after dosing

07

Study locations

8 sites
  • Capital Medical University Affiliated Beijing Ditan Hospital
    Beijing, Beijing Municipality 100015, China
  • The Second Affiliated Hospital of Chongqing Medical University
    Chongqing, Chongqing Municipality 400072, China
  • The Eighth Affiliated Hospital of Guangzhou Medical University
    Guangzhou, Guangdong 510405, China
  • Henan Provincial People's Hospital
    Zhengzhou, Henan 450003, China
  • Zhenjiang Third People's Hospital
    Zhenjiang, Jiangsu 212021, China
  • Jilin University First Hospital
    Changchun, Jilin 130033, China
  • Liaocheng People's Hospital
    Chaozhou, Shandong 252000, China
  • Qingdao Municipal Hospital
    Qingdao, Shandong 266001, China
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Jun 2025 to primary completion in Oct 2026, 16 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 22, 2026: primary completion May 2026 → Oct 2026 and completion Jun 2026 → Oct 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 26, 2026
First posted
Mar 3, 2026
StartActual
Jun 6, 2025
Primary completionActual
Oct 10, 2026was May 2026
CompletionActual
Oct 15, 2026was Jun 2026
Last update
Oct 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Oct 22, 2026
Primary completion
May 30, 2026→Oct 10, 2026 (actual)
Oct 22, 2026
Study completion
Jun 28, 2026→Oct 15, 2026 (actual)
Oct 22, 2026
Show all 1 update
  1. Oct 22, 2026
    Recruiting→Completed
    Primary completion May 30, 2026→Oct 10, 2026 (now actual)
    Study completion Jun 28, 2026→Oct 15, 2026 (now actual)
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07446491
Responsible party
Sponsor
First posted
Mar 3, 2026
Start date
Jun 6, 2025
Primary completion
Oct 10, 2026
Completion
Oct 15, 2026
Last update
Oct 22, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: PN20

Start the discussion